GlaxoSmithKline Pharmaceuticals Ltd
GlaxoSmithKline Pharmaceuticals's GHG Emissions Data Preview
In 2025, GlaxoSmithKline Pharmaceuticals completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources) and Scope 2 (indirect emissions from purchased energy).
However, GlaxoSmithKline Pharmaceuticals has not published a category-level breakdown of its Scope 3 emissions, limiting visibility into specific value chain sources.
| Metric (tCO2e) | 2025 | 2024 | 2023 | 2022 - 2017 |
|---|---|---|---|---|
Total Scope 1 | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  b | 0000000 |
Total Scope 2 | ||||
Unspecified Calculation Method | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  b | 0000000 |
Total Scope 3 | Copy restricted. Please purchase to unlock this data.  | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
Total Scope 1 Revenue Intensity (tCO2e/$M) | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  b | 0000000 |
Verified Sources Behind GlaxoSmithKline Pharmaceuticals’s Greenhouse Gas (GHG) Emissions Data
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore GlaxoSmithKline Pharmaceuticals’s data sources below and access millions more through our Disclosure Search.
Insights into GlaxoSmithKline Pharmaceuticals's Operational Emissions
In 2025, the total operational greenhouse gas (GHG) emissions of GlaxoSmithKline Pharmaceuticals amounted to 10,422 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2). a
Compared to 2024, the total operational greenhouse gas (GHG) emissions of GlaxoSmithKline Pharmaceuticals decreased by 2.89%, showing that the company has made progress in taking action to reduce the climate impact of its operations. a
GlaxoSmithKline Pharmaceuticals's Scope 1 Emissions Over Time
- Total Scope 1
- Year-over-Year Change
What are GlaxoSmithKline Pharmaceuticals's Scope 1 emissions?
In 2025, the total Scope 1 emissions of GlaxoSmithKline Pharmaceuticals were 1,002.89 metric tons of CO₂ equivalent (tCO₂e). a
Has GlaxoSmithKline Pharmaceuticals reduced its Scope 1 emissions over time?
Since 2023, GlaxoSmithKline Pharmaceuticals's Scope 1 emissions have increased by 105.95%, reflecting a rising long-term trend in Scope 1 emissions over time. a b
Compared to the previous year (2024), GlaxoSmithKline Pharmaceuticals's Scope 1 emissions increased by 29.52%, suggesting that the company faced challenges in reducing emissions from its directly owned or controlled operations. a
What are GlaxoSmithKline Pharmaceuticals's Scope 2 emissions?
In 2025, GlaxoSmithKline Pharmaceuticals reported Scope 2 greenhouse gas (GHG) emissions of 9,419.11 tCO₂e without specifying the calculation method. a
Has GlaxoSmithKline Pharmaceuticals reduced its Scope 2 emissions over time?
Since 2023, GlaxoSmithKline Pharmaceuticals's Scope 2 greenhouse gas (GHG) emissions ( Unspecified Calculation Method) have remained relatively stable, indicating that GlaxoSmithKline Pharmaceuticals 's emissions have plateaued with no significant change in its energy consumption footprint. a b
Compared to the previous year (2024), GlaxoSmithKline Pharmaceuticals's Scope 2 emissions (Unspecified Calculation Method) have remained relatively stable, indicating that GlaxoSmithKline Pharmaceuticals 's emissions have plateaued with no significant change in its energy consumption footprint. a
What methodology does GlaxoSmithKline Pharmaceuticals use for Scope 2 reporting?
In 2025, GlaxoSmithKline Pharmaceuticals reported its Scope 2 emissions using an unspecified methodology. a
GlaxoSmithKline Pharmaceuticals's Scope 2 Emissions Over Time
- Total Scope 2 (Unspecified Calculation Method)
Insights into GlaxoSmithKline Pharmaceuticals’s GHG Emissions Intensity Compared to Industry Peers
In 2025, GlaxoSmithKline Pharmaceuticals reported Scope 1 greenhouse gas (GHG) emissions of 1,002.89 tCO₂e and total revenues of USD 436 millions. This translates into an emissions intensity of 2.3 tCO₂e per millions USD. a
GlaxoSmithKline Pharmaceuticals's Scope 1 Emissions Intensity Compared to Peers
How does GlaxoSmithKline Pharmaceuticals's GHG emissions intensity compare to its peers?
In 2025, GlaxoSmithKline Pharmaceuticals reported a Scope 1 emissions intensity of 2.3 tCO₂e per millions USD. Compared to the peer group median of 18.88 , this places the company below its industry benchmark, indicating it is more carbon-efficient than most competitors. a
Where does GlaxoSmithKline Pharmaceuticals rank on GHG emissions intensity within its industry?
In 2025, GlaxoSmithKline Pharmaceuticals ranked 3 out of 24 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCO₂e per millions USD). a
This places GlaxoSmithKline Pharmaceuticals among the top performers, with one of the lowest emissions intensities relative to peers. a